Sanofi Injects 40 Million Euros to Strengthen Its Production in France

Sanofi is strengthening its production muscle. The French pharmaceutical company will invest forty million euros in its factory in Lyon Gerland, France, to advance the production of drugs to treat patients with kidney transplants and a new type of type 1 diabetes.

Specifically, the capital injection will help Sanofi to accelerate the production of the antibody Thymoglobulin, which specialises in kidney transplant rejection. In addition, the pharmaceutical company will be able to cover the needs for the development of the drug Tzield against diabetes.

The French company holds the patent for this drug, which was approved by the US Food and Drug Administration (FDA) at the end of 2022. Sanofi paid $2.9 billion early last year to buy Provention Bio.

The investment will be completed in two phases. First, 25 million euros will be dedicated to the manufacture and development of a second generation of Thymoglobulin, while the remaining fifteen million will be used to internalize and localize the production of the other drug .

Sanofi will start selling the transplant drug in 2025 and the diabetes drug in 2027

Sanofi’s factory in Lyon is currently the only one producing Thymoglobuline, with a production capacity of 1.6 million units for 70,000 patients per year. Specifically, the French group hopes to increase the production capacity of the immunosuppressant, making the supply more reliable.

The company plans to launch the first batches on the market in 2025 and the new version of Thymoglobulin in 2027. Sanofi also plans to develop a new bioproduction area for Tzield at the same plant in Lyon.

Sanofi closed the third quarter of the year with operating income, excluding extraordinary items, of 4.6 billion euros, 14.6% more than in the same period of the previous year.

Vaccine sales rose a currency-adjusted 25.5% to €3.8 billion in the quarter, above analysts’ consensus of €3.2 billion. Sanofi is set to sell a 50% stake in its consumer unit, valued at €16 billion in total, to boost clinical trials of next-generation drugs.

__

(Featured image by Myriam Zilles via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.